News archive
Showing 711 results
June 2026
-
Media Release
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety… -
Media Release
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous resultsDel-brax indicates potential to become… -
Media Release
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted … -
Media Release
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1 Vanrafia reduced protein in urine by 38.3%… -
Media Release
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent with established Cosentyx profile1,2… -
Media Release
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1 Clinically relevant 15.2%… -
Media Release
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase…
May 2026
-
Media Release
Pluvicto® demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAddition Consistent… -
Media Release
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented 124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be… -
Media Release
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali® NATALEE oral presentation to… -
Media Release
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto™ in metastatic hormone-sensitive prostate cancer
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone in PSMAddition Deep PSA reduction higher in patients receiving Pluvicto… -
Media Release
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the…